ChromaDex Corporation (CDXC) - 2024 Annual Report Summary
Business Context and Reporting Period
Company: ChromaDex Corporation (CDXC)
Filing Type: Form 10-K (Annual Report)
Period: Fiscal year ended December 31, 2024
Business Overview: ChromaDex is a global bioscience company focused on healthy aging, primarily through the development and commercialization of nicotinamide riboside chloride (NRC), branded as Niagen®. The company operates three segments: Consumer Products (Tru Niagen®), Ingredients (food-grade and pharmaceutical-grade Niagen®), and Analytical Reference Standards and Services. In 2024, the company launched Niagen Plus, a pharmaceutical-grade product line for clinics.
Key Financial Metrics
| Metric (in thousands) | 2024 | 2023 |
|---|---|---|
| Net Sales | $99,597 | $83,570 |
| Gross Profit | $61,586 | $50,780 |
| Gross Margin | 61.8% | 60.8% |
| Operating Income | $7,726 | $(5,599) |
| Net Income (Loss) | $8,550 | $(4,938) |
| Diluted EPS | $0.11 | $(0.07) |
| Cash and Cash Equivalents | $44,660 | $27,325 |
| Operating Cash Flow | $12,109 | $7,117 |
| Debt (Line of Credit) | $0 | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 19% year-over-year to $99.6 million. The Ingredients segment was the primary driver, surging 78% to $19.8 million due to new partnerships and the launch of pharmaceutical-grade Niagen®. Consumer Products sales grew 10% to $76.8 million.
- Profitability Turnaround: The company reported a net income of $8.6 million in 2024, a significant improvement from a net loss of $4.9 million in 2023. This turnaround was driven by revenue growth and a substantial reduction in General and Administrative (G&A) expenses.
- Expense Reduction: G&A expenses decreased 26% to $18.4 million. This was primarily due to a $3.5 million reversal of previously accrued royalties and license fees from Dartmouth College and a $2.2 million recovery of credit losses related to litigation settlements.
- Inventory Management: Total inventory decreased from $14.5 million in 2023 to $9.2 million in 2024, reflecting improved supply chain efficiency and lower bulk ingredient holdings.
Guidance, Outlook, Risks, and Unusual Items
- Unusual Items: The 2024 financial results include non-recurring benefits: a $3.5 million royalty waiver from Dartmouth College and a $1.3 million recovery of credit losses from a settlement with Elysium Health. Excluding these, the company's operational profitability remains strong but lower than reported.
- Outlook: Management anticipates current cash ($44.7 million) and operating cash flows will be sufficient for at least the next 12 months. However, the company may seek additional financing for long-term strategic objectives. The company has an At-The-Market (ATM) facility with approximately $47.8 million available.
- Key Risks:
- Supplier Concentration: The company relies exclusively on W.R. Grace for food-grade NRC. The supply agreement expires March 31, 2025, with a binding forecast obligating $11.2 million in purchases through June 2025. Failure to renew could materially impact operations.
- Legal Contingencies: While the California action against Elysium Health was settled for $2.65 million, a Delaware patent infringement case remains. The court awarded Elysium $9.2 million in fees and costs. ChromaDex has appealed; if unsuccessful, the company estimates a potential liability of approximately $10.4 million.
- Regulatory: The company faces ongoing regulatory scrutiny regarding marketing claims and the status of NRC on the FDA's list of bulk drug substances for compounding.
Investor Verification Checklist
- Supplier Renewal: Verify the status of the manufacturing agreement renewal with W.R. Grace, which is critical for the supply of the core ingredient (NRC).
- Legal Exposure: Monitor the appeal process in the Delaware patent infringement case against Elysium Health, which could result in a $10.4 million liability.
- Recurring Profitability: Assess the company's ability to maintain profitability excluding the one-time $3.5 million royalty reversal and $1.3 million credit loss recovery.
- Pharmaceutical-Grade Growth: Track the adoption rate of the new pharmaceutical-grade Niagen® (Niagen Plus) in the 503B outsourcing facility market.
- Cash Burn vs. Generation: Confirm that operating cash flow remains positive and sufficient to cover the $11.2 million in near-term inventory purchase commitments without immediate dilution.